Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Syndax Pharmaceuticals (SNDX) Return on Sales (2016 - 2021)

Syndax Pharmaceuticals (SNDX) has disclosed Return on Sales for 7 consecutive years, with 52.26% as the latest value for Q3 2021.

  • For Q3 2021, Return on Sales rose 12.0% year-over-year to 52.26%; the TTM value through Sep 2021 reached 52.26%, down 891.0%, while the annual FY2025 figure was 1.45%, 1179.0% up from the prior year.
  • Return on Sales hit 52.26% in Q3 2021 for Syndax Pharmaceuticals, roughly flat from 52.32% in the prior quarter.
  • Across five years, Return on Sales topped out at 15.95% in Q4 2017 and bottomed at 52.38% in Q3 2020.
  • Average Return on Sales over 5 years is 44.54%, with a median of 47.07% recorded in 2018.
  • Year-over-year, Return on Sales surged 1970bps in 2017 and then tumbled -3493bps in 2018.
  • Syndax Pharmaceuticals' Return on Sales stood at 15.95% in 2017, then tumbled by -219bps to 50.88% in 2018, then grew by 27bps to 37.38% in 2019, then crashed by -40bps to 52.26% in 2020, then changed by 0bps to 52.26% in 2021.
  • According to Business Quant data, Return on Sales over the past three periods came in at 52.26%, 52.32%, and 49.49% for Q3 2021, Q2 2021, and Q1 2021 respectively.